WO2022042644A1 - 依达拉奉缓释药物组合物、制备方法及应用 - Google Patents

依达拉奉缓释药物组合物、制备方法及应用 Download PDF

Info

Publication number
WO2022042644A1
WO2022042644A1 PCT/CN2021/114757 CN2021114757W WO2022042644A1 WO 2022042644 A1 WO2022042644 A1 WO 2022042644A1 CN 2021114757 W CN2021114757 W CN 2021114757W WO 2022042644 A1 WO2022042644 A1 WO 2022042644A1
Authority
WO
WIPO (PCT)
Prior art keywords
edaravone
pharmaceutical composition
pharmaceutical
hypromellose
sustained
Prior art date
Application number
PCT/CN2021/114757
Other languages
English (en)
French (fr)
Inventor
郭桢
陈丽
谢文凤
王婷婷
应述欢
Original Assignee
上海博志研新药物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海博志研新药物技术有限公司 filed Critical 上海博志研新药物技术有限公司
Publication of WO2022042644A1 publication Critical patent/WO2022042644A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the invention relates to an edaravone sustained-release pharmaceutical composition, a preparation method and an application.
  • Edaravone is a brain protectant (free radical scavenger).
  • N-acetylaspartic acid NAA
  • Edaravone given to patients in the acute stage of cerebral infarction can inhibit the reduction of local cerebral blood flow around the infarction, and the NAA content in the brain on the 28th day after the onset of the disease is significantly higher than that of the glycerol control group. Therefore, edaravone is used to improve acute cerebral infarction. Neurological symptoms, activities of daily living, and functional impairment due to infarction.
  • the marketed edaravone preparation is an injection, usually 30 mg of edaravone for adults, 2 times a day, diluted with an appropriate amount of normal saline, and intravenously infused within 30 minutes. Dosing was started within 24 hours of onset, and the course of treatment was 14 days.
  • Patients with twice-daily intravenous infusions have poor compliance and toxic side effects include acute renal failure, liver dysfunction, jaundice, thrombocytopenia, disseminated intravascular coagulation (DIC), injection site rash, redness, herpes, and itching Sensation, belching, fever, heat sensation, increased blood pressure, increased serum cholesterol, decreased serum cholesterol, increased triacylglycerol, decreased serum total protein, decreased creatine kinase (CK), creatine phosphokinase (CPK), serum calcium low.
  • DIC disseminated intravascular coagulation
  • DIC disseminated intravascular coagulation
  • injection site rash redness, herpes
  • itching Sensation belching, fever, heat sensation
  • increased blood pressure increased serum cholesterol, decreased serum cholesterol, increased triacylglycerol
  • decreased serum total protein decreased creatine kinase (CK), creatine phosphokinase (CPK), serum calcium low.
  • CK creatine kinase
  • Edaravone is soluble in methanol and ethanol, and its solubility in water is less than 1 mg/mL.
  • the pKa of edaravone is 7.0, and the solubility in water is pH-dependent, which is basically unchanged from pH2-pH7, and gradually increases from pH8 to pH10.
  • the present invention provides a pharmaceutical composition, wherein the pharmaceutical composition has the following features A), B) and C):
  • the pharmaceutical active ingredient can be selected from one or more of edaravone, its pharmaceutically acceptable salts, hydrates and solvates.
  • the pharmaceutical composition preferably has the following characteristics A), B) and C):
  • the pharmaceutical composition more preferably has the following characteristics A), B) and C):
  • the “dissolution” refers to the cumulative dissolution rate of a pharmaceutical active ingredient (such as edaravone); further, the cumulative dissolution rate is measured in pH 6.8 phosphate buffer.
  • a pharmaceutical active ingredient such as edaravone
  • the dissolution rate of the active pharmaceutical ingredient gradually increases with time.
  • the pharmaceutical composition is a sustained-release composition, preferably a sustained-release pharmaceutical composition within 24 hours.
  • the present invention also provides a pharmaceutical composition, which includes the following components: a drug layer and a coating layer; the drug layer includes edaravone active pharmaceutical ingredients, a polymer carrier, a matrix sustained-release material and other auxiliary materials;
  • the other adjuvants mentioned include one or more of fillers, binders, disintegrants and lubricants.
  • the coating layer is preferably a film coating.
  • the Edaravone pharmaceutical active ingredient may be selected from one or more of Edaravone, its pharmaceutically acceptable salts, hydrates and solvates.
  • the solvent in the Edaravone solvate can be an organic solvent
  • the organic solvent can be an organic solvent known in the art, such as methanol, ethanol, tetrahydrofuran, and diethyl ether, etc. one or more.
  • the content of the edaravone pharmaceutical active ingredient is preferably 5.0% to 65.0%, such as 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10.0%, 11.0%, 12.0% , 13.0%, 14.0%, 15.0%, 20.0%, 25.0%, 30.0%, 35.0%, 40.0%, 45.0%, 50.0%, 55.0%, 60.0% or 65.0%; Calculated as daravone, the weight of the edaravone pharmaceutical active ingredient as a percentage of the total weight of the pharmaceutical composition.
  • the polymer carrier is selected from polyethylene glycol, copovidone (PVP/VA), hypromellose (such as K4M or K100Lv), hypromellose acetate succinate (HPMCAS), one or more of hypromellose phthalate (HPMCP), polyvinyl acetate povidone blend, poloxamers, and carboxymethyl ethyl cellulose (CMEC) .
  • PVP/VA polyethylene glycol
  • hypromellose such as K4M or K100Lv
  • HPMCAS hypromellose acetate succinate
  • HPMCP hypromellose phthalate
  • CMEC carboxymethyl ethyl cellulose
  • the content of the polymer carrier is preferably 10.0% to 80.0%, and the content refers to the percentage of the weight of the polymer carrier to the total weight of the pharmaceutical composition.
  • the matrix sustained-release material is preferably hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium alginate, carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose , polyacrylic resin, ethyl cellulose, carbomer, stearic acid, polyoxyethylene, polyvinyl acetate povidone mixture, glyceryl monostearate, glyceryl distearate, glyceryl behenate One or more of , cetyl alcohol, stearyl alcohol, beeswax, hydrogenated castor oil, carnauba wax, paraffin wax, white wax and microcrystalline wax.
  • the content of the matrix sustained-release material is preferably 5.0% to 50.0%, such as 5.0%, 10.0%, 15.0%, 20.0%, 25.0%, 30.0%, 35.0%, 40.0%, 45.0% or 50.0%; wherein, the content refers to the percentage of the weight of the matrix sustained-release material in the total weight of the pharmaceutical composition.
  • the filler may be a filler known in the art, preferably among microcrystalline cellulose, pregelatinized starch, starch, lactose, mannitol, calcium hydrogen phosphate and silicified microcrystalline cellulose
  • a filler known in the art preferably among microcrystalline cellulose, pregelatinized starch, starch, lactose, mannitol, calcium hydrogen phosphate and silicified microcrystalline cellulose
  • One or more of for example, it can be one or more of starch, lactose and mannitol.
  • the matrix sustained-release material adopts a hydrophilic gel matrix material
  • a water-soluble auxiliary material such as lactose, mannitol and starch etc.
  • the water-soluble auxiliary material such as lactose, mannitol and starch etc.
  • the water-soluble auxiliary material dissolves (such as lactose, mannitol and starch, etc.), increase the porosity, act as a pore-forming agent, and control the release performance together with the matrix sustained-release material.
  • the content of the filler is preferably 10.0% to 60.0%, such as 10.0%, 11.0%, 12.0%, 13.0%, 14.0%, 15.0%, 20.0%, 25.0%, 30.0%, 35.0% %, 40.0%, 45.0%, 50.0%, 55.0% or 60.0%; wherein, the content refers to the percentage of the weight of the filler in the total weight of the pharmaceutical composition.
  • the adhesive can be a sticky substance known in the art, preferably povidone (also known as polyvinylpyrrolidone, PVP), methyl cellulose, hydroxypropyl methyl cellulose One or more of cellulose, hydroxyethyl cellulose, copovidone, sodium carboxymethyl cellulose, hydroxypropyl cellulose and sodium alginate.
  • povidone also known as polyvinylpyrrolidone, PVP
  • PVP polyvinylpyrrolidone
  • the content of the binder is preferably 5.0% to 30.0%, such as 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10.0%, 11.0%, 12.0%, 13.0%, 14.0%, 15.0%, 20.0%, 25.0% or 30.0%; wherein, the content refers to the percentage of the weight of the adhesive in the total weight of the pharmaceutical composition.
  • the disintegrating agent can be a conventional material with disintegrating effect in the art, preferably crospovidone, croscarmellose sodium, croscarmellose One or more of calcium, sodium carboxymethyl starch, hydroxypropyl cellulose and pregelatinized starch, more preferably crospovidone, croscarmellose sodium and croscarmellose calcium one or more of.
  • the lubricant can be a substance with lubricating effect, preferably calcium stearate, magnesium stearate, zinc stearate, stearic acid, sodium fumarate stearate, polyethylene One or more of glycol, starch, talc and paraffin, and more preferably one or more of magnesium stearate, calcium stearate and stearic acid.
  • the content of the lubricant is preferably 0% to 5%, such as 0.1%, 0.5%, 1.0%, 2.0%, 3.0%, 4.0% or 5.0%; wherein, the content is Refers to the weight of the lubricant as a percentage of the total weight of the pharmaceutical composition.
  • the content of the other excipients is preferably 30.0% to 80.0%, such as 30.0%, 35.0%, 40.0%, 45.0%, 50.0%, 55.0%, 6.0%, 65.0%, 70.0%, 75.0% % or 80.0%; wherein, the content refers to the percentage of the weight of other adjuvants in the total weight of the pharmaceutical composition.
  • the pharmaceutical composition preferably has any of the following components by weight:
  • Component 1 10.0%-30.0% active pharmaceutical ingredients of edaravone, 10.0%-30.0% hypromellose acetate succinate, 10.0%-30.0% hypromellose K4M, 5.0%-20.0% hydroxyl Promethylcellulose K100Lv, 10.0%-30.0% lactose, 5.0%-20.0% microcrystalline cellulose and 0.5%-2.0% magnesium stearate;
  • Component 2 10.0%-30.0% active pharmaceutical ingredients of edaravone, 10.0%-30.0% hypromellose acetate succinate, 10.0%-30.0% hypromellose K100Lv, 10.0%-30.0% pre- gelatinized starch, 5.0%-20.0% crospovidone, 5.0%-20.0% microcrystalline cellulose and 0.5%-2.0% magnesium stearate;
  • Component three 10.0%-30.0% edaravone pharmaceutical active ingredients, 40.0%-60.0% hypromellose acetate succinate, 5.0%-20.0% hypromellose K4M, 5.0%-20.0% hydroxypropyl methylcellulose Promethylcellulose K100Lv, 5.0%-20.0% lactose, 5.0%-20.0% microcrystalline cellulose and 0.5%-2.0% magnesium stearate;
  • Component four 10.0%-30.0% edaravone pharmaceutical active ingredients, 40.0%-60.0% hypromellose acetate succinate, 5.0%-20.0% hypromellose K100Lv, 5.0%-20.0% pre- gelatinized starch, 5.0%-20.0% crospovidone, 5.0%-20.0% microcrystalline cellulose and 0.5%-2.0% magnesium stearate;
  • the pharmaceutical composition can also be any component with the following weight percentages:
  • Component 1 20.00% Edaravone Active Pharmaceutical Ingredients, 20.00% Hypromellose Acetate Succinate, 20.00% Hypromellose K4M, 10.00% Hypromellose K100Lv, 19.00% Lactose, 10.00% Microcrystalline cellulose and 1.00% magnesium stearate;
  • Component 2 20.00% edaravone active pharmaceutical ingredients, 20.00% hypromellose acetate succinate, 19.00% hypromellose K100Lv, 20.00% pregelatinized starch, 10.00% crospovidone, 10.00% microcrystalline cellulose and 1.00% magnesium stearate;
  • Component three 16.67% edaravone active pharmaceutical ingredients, 50.00% hypromellose acetate succinate, 8.33% hypromellose K4M, 8.33% hypromellose K100Lv, 8.33% lactose, 7.34% Microcrystalline cellulose and 1.00% magnesium stearate;
  • Component four 16.67% edaravone active ingredient, 50% hypromellose acetate succinate, 8.33% hypromellose K100Lv, 8.33% pregelatinized starch, 7.34% crospovidone, 8.33% microcrystalline cellulose and 1.00% magnesium stearate.
  • the content or ratio of edaravone pharmaceutically active ingredient in the context of the present invention is based on edaravone.
  • the present invention also provides an edaravone pharmaceutical active ingredient dispersion, comprising the edaravone pharmaceutical active ingredient dispersed in a polymer carrier.
  • the polymer carrier is selected from polyethylene glycol, copovidone, hypromellose, hypromellose acetate succinate, hypromellose phthalate, polyacetate One or more of vinyl ester povidone mixture, poloxamer and carboxymethyl ethyl cellulose.
  • the mass ratio of the active pharmaceutical ingredient of edaravone to the polymer carrier may be 1:1 or lower, such as 1:2, 1 :3, 1:4, 1:5, 1:6 or lower.
  • the present invention also provides a pharmaceutical composition, wherein the pharmaceutical composition comprises the edaravone pharmaceutical active ingredient dispersion.
  • the pharmaceutical composition may be a sustained-release preparation, preferably a sustained-release solid preparation, such as one selected from the group consisting of sustained-release tablets, sustained-release capsules, and sustained-release pellets.
  • the present invention also provides a preparation method of the pharmaceutical composition, which can be selected from wet granulation (such as fluidized bed granulation or high shear granulation), dry granulation or direct compression and the like.
  • wet granulation such as fluidized bed granulation or high shear granulation
  • dry granulation or direct compression and the like.
  • wet granulation preferably includes the following steps: dissolving the active pharmaceutical ingredient of edaravone and hypromellose acetate succinate in methanol/water solution, and spray-drying to obtain the active pharmaceutical ingredient of edaravone Ingredient solid dispersion; the solid dispersion of edaravone pharmaceutical active ingredient is mixed with matrix sustained-release material and some other excipients (including one or more of binders, fillers and disintegrants), and wet granulation , drying, granulating, and then mixing with lubricant, tableting, and coating (film coating) to obtain edaravone medicated active ingredient sustained-release tablets.
  • dry granulation preferably includes the following steps: dissolving the active pharmaceutical ingredients of Edaravone and hypromellose acetate succinate in methanol/water solution, and spray drying to obtain the active pharmaceutical Edaravone Ingredient solid dispersion; the edaravone pharmaceutical active ingredient solid dispersion with matrix sustained-release material and some other excipients (including one or more of binders, fillers, disintegrants and lubricants), dry
  • the method is granulated, and then mixed with an external lubricant, compressed into a tablet, and coated (film coating) to obtain a sustained-release tablet of the active ingredient of edaravone.
  • the direct compression method preferably includes the following steps: dissolving the active ingredient of edaravone and hypromellose acetate succinate in methanol/water solution, and spray-drying to obtain the edaravone drug Active ingredient solid dispersion; the edaravone pharmaceutical active ingredient solid dispersion is mixed with the matrix sustained-release material and other auxiliary materials, tableted, and coated (film coating) to obtain the edaravone pharmaceutical active ingredient sustained-release tablet.
  • the present invention also provides the application of the pharmaceutical composition in preparing a medicine for treating and/or preventing oxidative stress-related diseases.
  • the present invention also provides a method of treating and/or preventing oxidative stress-related diseases, comprising administering the pharmaceutical composition to a patient (eg, a human) in need thereof.
  • the oxidative stress-related disease is selected from the group consisting of Alzheimer's disease (Alzheimer's disease), ALS (Amyotrophic lateral sclerosis), Parkinson's disease, ischemic heart disease, Cerebral infarction/stroke, thrombophlebitis, COPD (chronic obstructive pulmonary disease), HIV/AIDS (human immune system disease/acquired immune system syndrome) and diabetes.
  • Alzheimer's disease Alzheimer's disease
  • ALS Amyotrophic lateral sclerosis
  • Parkinson's disease ischemic heart disease
  • Cerebral infarction/stroke Cerebral infarction/stroke
  • thrombophlebitis chronic obstructive pulmonary disease
  • HIV/AIDS human immune system disease/acquired immune system syndrome
  • the positive improvement effect of the present invention is that: the pharmaceutical composition of the present invention can be taken once a day, and the drug can be slowly released within 24 hours, so that it can maintain a stable and effective blood drug concentration in the body for a long time, reduce the number of administrations, and improve the Patient compliance and good market prospects.
  • Step 2 The solution in step 1 is spray-dried with a spray dryer to obtain the edaravone solid dispersion, and the edaravone solid dispersion is passed through a 40-mesh sieve;
  • Step 3 Place the edaravone solid dispersion processed in step 2 and other auxiliary materials except magnesium stearate in a three-dimensional mixer, set the mixing speed to 18r/min, and mix for 20 minutes; then add stearic acid Magnesium, set the mixing speed to 18r/min, and mix for 5 minutes;
  • Step 4 The material obtained in step 3 is then placed on a rotary tableting machine, and pressed into an oval tablet core with a single tablet of 500 mg and a hardness of 80N to 160N;
  • Step 5 The plain tablet obtained in Step 4 is coated with a stomach-dissolving film coating premix (Opadry) to obtain a film-coated tablet.
  • a stomach-dissolving film coating premix Opadry
  • Step 2 The solution in step 1 is spray-dried with a spray dryer to obtain the edaravone solid dispersion, and the edaravone solid dispersion is passed through a 40-mesh sieve;
  • Step 3 Place the Edaravone solid dispersion processed in Step 2 and other auxiliary materials except magnesium stearate in a three-dimensional mixer, set the mixing speed to 18r/min, and mix for 20 minutes; Magnesium stearate, set the mixing speed to 18r/min, and mix for 5 minutes;
  • Step 4 Place the mixture obtained in step 3 in a dry granulator, adjust the equipment parameters so that it can be compressed into large pieces with a certain hardness, and then use a 1.0mm screen to granulate; Mix, set the mixing speed to 18r/min, and mix for 5 minutes;
  • Step 5 The material obtained in step 4 is then placed on a rotary tableting machine, and compressed into an oval tablet core with a single tablet of 600 mg and a hardness of 100N to 180N;
  • Step 6 The plain tablet obtained in Step 5 is coated with a stomach-dissolving film coating premix (Opadry) to obtain a film-coated tablet.
  • a stomach-dissolving film coating premix Opadry
  • the dissolution results are as follows:
  • edaravone is prepared into an amorphous solid dispersion , which is beneficial to improve its solubility and bioavailability; it is prepared into a sustained-release dosage form, which can stabilize the blood drug concentration in the body and reduce the toxic and side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

一种依达拉奉缓释药物组合物、制备方法及应用。一种依达拉奉缓释药物组合物，其包括以下组分：药物层和包衣层；药物层包括依达拉奉药物活性成分、骨架缓释材料和其他辅料；其他辅料包括填充剂、粘合剂和润滑剂中的一种或多种。依达拉奉缓释药物组合物，可每日服药1次，在24小时内缓慢释放药物，使其可长期在体内维持平稳有效的血药浓度，减少给药次数，改善患者顺应性，市场化前景好。

Description

依达拉奉缓释药物组合物、制备方法及应用
本申请要求享有2020年8月26日向中国国家知识产权局提交的申请号为202010871330.3，名称为“依达拉奉缓释药物组合物、制备方法及应用”的发明专利申请的优先权。该申请的全文以引用的方式并入本文。
技术领域
本发明涉及一种依达拉奉缓释药物组合物、制备方法及应用。
背景技术
依达拉奉是一种脑保护剂(自由基清除剂)。临床研究提示N-乙酰门冬氨酸(NAA)是特异性的存活神经细胞的标志，脑梗塞发病初期含量急剧减少。脑梗塞急性期患者给予依达拉奉，可抑制梗塞周围局部脑血流量的减少，使发病后第28天脑中NAA含量较甘油对照组明显升高，因此依达拉奉用于改善急性脑梗塞所致的神经症状、日常生活活动能力和功能障碍。
上市依达拉奉制剂为注射液，通常成人依达拉奉30mg，一日2次，用时以适量的生理盐水稀释，30分钟内静脉滴注完。发病后24小时内开始给药，疗程为14天。一天2次静脉滴注患者的顺应性较差，且毒副作用包括急性肾功能衰竭、肝功能障碍、黄疸、血小板减少、弥散性血管内凝血(DIC)，注射部位发疹、红肿，疱疹，瘙痒感，嗳气，发热，热感，血压上升，血清胆固醇升高，血清胆固醇降低，三酰甘油升高，血清总蛋白减少，肌酸激酶(CK)、肌酸磷酸激酶(CPK)降低，血清钙低下。
依达拉奉在甲醇、乙醇中溶解，在水中溶解度小于1mg/mL。依达拉奉的pKa为7.0，水中的溶解度具有pH依赖性，从pH2-pH7基本不变，从pH8到pH 10溶解度逐渐增加。
因此有必要开发一种依达拉奉口服缓释制剂，提高其生物利用度、释药 速度平稳，可显著提高患者用药顺应性及降低毒副作用。
发明内容
为改善上述技术问题，本发明提供一种药物组合物，其中所述药物组合物具有以下特征A)、B)和C)：
A)在1小时内溶出不超过35％的药物活性成分；
B)在6小时内溶出30％～65％的药物活性成分；
C)在24小时内溶出不低于75％的药物活性成分；
其中，所述的药物活性成分可以选自依达拉奉、其药学上可接受的盐、水合物和溶剂合物中的一种或多种。
根据本发明的实施方案，所述药物组合物优选具有以下特征A)、B)和C)：
A)在1小时内溶出不超过30％的药物活性成分；
B)在6小时内溶出30％～60％的药物活性成分；
C)在24小时内溶出不低于75％的药物活性成分；
根据本发明的实施方案，所述药物组合物更优选具有以下特征A)、B)和C)：
A)在1小时内溶出不超过25％的药物活性成分；
B)在6小时内溶出35％～60％的药物活性成分；
C)在24小时内溶出不低于80％的药物活性成分。
其中，所述“溶出”指药物活性成分(如依达拉奉)的累积溶出度；进一步地，所述累积溶出度在pH 6.8磷酸盐缓冲液中测得。本领域技术人员能够理解，随着时间增加，所述药物活性成分(如依达拉奉)的溶出度逐渐增加。
根据本发明的实施方案，所述药物组合物为缓释组合物，优选为24小时内持续缓释的药物组合物。
本发明还提供一种药物组合物，其包括以下组分：药物层和包衣层；所述的药物层包括依达拉奉药物活性成分、聚合物载体、骨架缓释材料和其他 辅料；所述的其他辅料包括填充剂、粘合剂、崩解剂和润滑剂中的一种或多种。
根据本发明的实施方案，所述的包衣层优选为薄膜包衣。
根据本发明的实施方案，所述的依达拉奉药物活性成分可以选自依达拉奉、其药学上可接受的盐、水合物和溶剂合物中的一种或多种。
根据本发明的实施方案，所述的依达拉奉溶剂合物中的溶剂可以为有机溶剂，所述有机溶剂可以为本领域已知的有机溶剂，例如甲醇、乙醇、四氢呋喃和乙醚等中的一种或多种。
根据本发明的实施方案，所述的依达拉奉药物活性成分的含量优选5.0％～65.0％，例如5.0％、6.0％、7.0％、8.0％、9.0％、10.0％、11.0％、12.0％、13.0％、14.0％、15.0％、20.0％、25.0％、30.0％、35.0％、40.0％、45.0％、50.0％、55.0％、60.0％或65.0％；其中，所述的含量是指以依达拉奉计，依达拉奉药物活性成分的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的聚合物载体选自聚乙二醇、共聚维酮(PVP/VA)、羟丙甲纤维素(如K4M或K100Lv)、醋酸羟丙甲纤维素琥珀酸酯(HPMCAS)、羟丙甲纤维素邻苯二甲酸酯(HPMCP)、聚醋酸乙烯酯聚维酮混合物、泊洛沙姆和羧甲基乙基纤维素(CMEC)中的一种或多种。
根据本发明的实施方案，所述的聚合物载体的含量优选10.0％～80.0％，所述的含量是指聚合物载体的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的骨架缓释材料优选羟丙基甲基纤维素、羟丙基纤维素、海藻酸钠、羧甲基纤维素、羧甲基纤维素钠、甲基纤维素、聚丙烯酸树脂、乙基纤维素、卡波姆、硬脂酸、聚氧乙烯、聚醋酸乙烯酯聚维酮混合物、单硬脂酸甘油酯、双硬脂酸甘油酯、山嵛酸甘油酯、十六醇、十八醇、蜂蜡、氢化蓖麻油、巴西棕榈蜡、石蜡、白蜡和微晶蜡中的一种或多种。
根据本发明的实施方案，所述的骨架缓释材料的含量优选5.0％～50.0％，例如5.0％、10.0％、15.0％、20.0％、25.0％、30.0％、35.0％、40.0％、45.0％ 或50.0％；其中，所述的含量是指骨架缓释材料的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的填充剂可以为本领域已知的填充剂，优选微晶纤维素、预胶化淀粉、淀粉、乳糖、甘露醇、磷酸氢钙和硅化微晶纤维素中的一种或多种；例如可以为淀粉、乳糖和甘露醇中的一种或多种。
当骨架缓释材料采用亲水凝胶骨架材料时，优选水溶性辅料作为填充剂，所述的水溶性辅料例如乳糖、甘露醇和淀粉等，其优点在于难溶性药物释放时，水溶性辅料溶解(例如乳糖、甘露醇和淀粉等)，提高孔隙率，充当致孔剂，与骨架缓释材料共同控制释放性能。
根据本发明的实施方案，所述的填充剂的含量优选10.0％～60.0％，例如10.0％、11.0％、12.0％、13.0％、14.0％、15.0％、20.0％、25.0％、30.0％、35.0％、40.0％、45.0％、50.0％、55.0％或60.0％；其中，所述的含量是指填充剂的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的粘合剂可以为本领域已知的具有粘性的物质，优选聚维酮(又名聚乙烯吡咯烷酮，PVP)、甲基纤维素、羟丙基甲基纤维素、羟乙基纤维素、共聚维酮、羧甲基纤维素钠、羟丙基纤维素和海藻酸钠中的一种或多种。
根据本发明的实施方案，所述的粘合剂的含量优选5.0％～30.0％，例如5.0％、6.0％、7.0％、8.0％、9.0％、10.0％、11.0％、12.0％、13.0％、14.0％、15.0％、20.0％、25.0％或30.0％；其中，所述的含量是指粘合剂的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的崩解剂可以为本领域中常规的具有崩解作用的物质，优选交联聚维酮、交联羧甲基纤维素钠、交联羧甲基纤维素钙、羧甲基淀粉钠，羟丙纤维素和预胶化淀粉中的一种或多种，进一步优选交联聚维酮、交联羧甲基纤维素钠和交联羧甲基纤维素钙中的一种或多种。
根据本发明的实施方案，所述的润滑剂可以为具有润滑作用的物质，优选硬脂酸钙、硬脂酸镁、硬脂酸锌、硬脂酸、硬脂酸富马酸钠、聚乙二醇、 淀粉、滑石粉和石蜡中的一种或多种，进一步优选硬脂酸镁、硬脂酸钙和硬脂酸中的一种或多种。
根据本发明的实施方案，所述的润滑剂的含量优选0％～5％，例如0.1％、0.5％、1.0％、2.0％、3.0％、4.0％或5.0％；其中，所述的含量是指润滑剂的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的其他辅料的含量优选30.0％～80.0％，例如30.0％、35.0％、40.0％、45.0％、50.0％、55.0％、6.0％、65.0％、70.0％、75.0％或80.0％；其中，所述的含量是指其他辅料的重量占药物组合物总重量的百分比。
根据本发明的实施方案，所述的药物组合物优选具有以下重量百分比的任一组分：
组分一：10.0％-30.0％依达拉奉药物活性成分，10.0％-30.0％醋酸羟丙甲纤维素琥珀酸酯，10.0％-30.0％羟丙甲纤维素K4M，5.0％-20.0％羟丙甲纤维素K100Lv，10.0％-30.0％乳糖，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
组份二：10.0％-30.0％依达拉奉药物活性成分，10.0％-30.0％醋酸羟丙甲纤维素琥珀酸酯，10.0％-30.0％羟丙甲纤维素K100Lv，10.0％-30.0％预胶化淀粉，5.0％-20.0％交联聚维酮，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
组分三：10.0％-30.0％依达拉奉药物活性成分、40.0％-60.0％醋酸羟丙甲纤维素琥珀酸酯，5.0％-20.0％羟丙甲纤维素K4M，5.0％-20.0％羟丙甲纤维素K100Lv，5.0％-20.0％乳糖，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
组分四：10.0％-30.0％依达拉奉药物活性成分，40.0％-60.0％醋酸羟丙甲纤维素琥珀酸酯，5.0％-20.0％羟丙甲纤维素K100Lv，5.0％-20.0％预胶化淀粉，5.0％-20.0％交联聚维酮，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
根据本发明的实施方案，所述的药物组合物也可以为具有以下重量百分比的任一组分：
组分一：20.00％依达拉奉药物活性成分，20.00％醋酸羟丙甲纤维素琥珀酸酯，20.00％羟丙甲纤维素K4M，10.00％羟丙甲纤维素K100Lv，19.00％乳糖，10.00％微晶纤维素和1.00％硬脂酸镁；
组份二：20.00％依达拉奉药物活性成分，20.00％醋酸羟丙甲纤维素琥珀酸酯，19.00％羟丙甲纤维素K100Lv，20.00％预胶化淀粉，10.00％交联聚维酮，10.00％微晶纤维素和1.00％硬脂酸镁；
组分三：16.67％依达拉奉药物活性成分、50.00％醋酸羟丙甲纤维素琥珀酸酯，8.33％羟丙甲纤维素K4M，8.33％羟丙甲纤维素K100Lv，8.33％乳糖，7.34％微晶纤维素和1.00％硬脂酸镁；
组分四：16.67％依达拉奉药物活性成分，50％醋酸羟丙甲纤维素琥珀酸酯，8.33％羟丙甲纤维素K100Lv，8.33％预胶化淀粉，7.34％交联聚维酮，8.33％微晶纤维素和1.00％硬脂酸镁。
除非另有说明，本发明上下文中依达拉奉药物活性成分的含量或比例以依达拉奉计。
本发明还提供一种依达拉奉药物活性成分分散体，包括分散于聚合物载体中的依达拉奉药物活性成分。优选地，所述的聚合物载体选自聚乙二醇、共聚维酮、羟丙甲纤维素、醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯、聚醋酸乙烯酯聚维酮混合物、泊洛沙姆和羧甲基乙基纤维素中的一种或多种。
根据本发明的实施方案，在所述依达拉奉药物活性成分分散体中，依达拉奉药物活性成分与聚合物载体的质量比可以为1:1或更低，例如1:2、1:3、1:4、1:5、1:6或更低。
本发明还提供一种药物组合物，其中所述药物组合物包含所述依达拉奉药物活性成分分散体。
根据本发明的实施方案，所述的药物组合物可以为缓释制剂，优选缓释固体制剂，例如选自缓释片、缓释胶囊和缓释微丸等剂型中的一种。
本发明还提供了所述药物组合物的制备方法，其可以选自湿法制粒法 (例如流化床制粒法或高剪切制粒)，干法制粒法或直接压片法等。
根据本发明的实施方案，湿法制粒优选包括以下步骤：将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中，经喷雾干燥得依达拉奉药物活性成分固体分散体；将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料(包括粘合剂、填充剂和崩解剂中的一种或多种)混合，湿法制粒，干燥，整粒，然后再与润滑剂混合，压片，包衣(薄膜包衣)，即得到依达拉奉药物活性成分缓释片。
根据本发明的实施方案，干法制粒优选包括以下步骤：将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中，经喷雾干燥得依达拉奉药物活性成分固体分散体；将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料(包括粘合剂、填充剂、崩解剂和润滑剂中的一种或多种)，干法制粒，然后再与外加润滑剂混合，压片，包衣(薄膜包衣)即得到依达拉奉药物活性成分缓释片。
根据本发明的实施方案，直接压片法优选包括以下步骤：将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中，经喷雾干燥得依达拉奉药物活性成分固体分散体；将依达拉奉药物活性成分固体分散体与骨架缓释材料和其他辅料混合，压片，包衣(薄膜包衣)得到依达拉奉药物活性成分缓释片。
本发明还提供所述的药物组合物在制备治疗和/或预防氧化性应激相关疾病的药物中的应用。
本发明还提供一种治疗和/或预防氧化性应激相关疾病的方法，包括将所述药物组合物给予有需要的患者(例如人)。
根据本发明的实施方案，所述的氧化性应激相关疾病选自老年痴呆症(阿尔茨海默症)、ALS(肌萎缩侧索硬化症)、帕金森氏病、缺血性心脏病、脑梗/中风、血栓性静脉炎、COPD(慢性阻塞性肺疾病)、HIV/AIDS(人类免疫系统病/获得性免疫系统综合症)和糖尿病。
本发明的积极进步效果在于：本发明的药物组合物，可每日服药1次，在24小时内缓慢释放药物，使其可长期在体内维持平稳有效的血药浓度，减少给药次数，改善患者顺应性，市场化前景好。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
除非另有说明，下文实施例所使用的原料和试剂是可商购的或可由本领域技术人员通过已知的方法制备。
实施例1-2
依达拉奉缓释片处方组成
Figure PCTCN2021114757-appb-000001
Figure PCTCN2021114757-appb-000002
制备工艺：
步骤1：将上述处方中的依达拉奉和HPMCAS加入到溶剂中(甲醇：水＝9:1)，将样品置于恒温水浴锅中搅拌，设置加热温度50℃，进行溶解；
步骤2：将步骤1中的溶液使用喷雾干燥机进行喷雾干燥，得依达拉奉固体分散体，将依达拉奉固体分散体过40目筛网；
步骤3：将步骤2中处理好的依达拉奉固体分散体与除硬脂酸镁外的其他辅料置于三维混合机中，设置混合速度18r/min，混合20分钟；再加入硬脂酸镁，设置混合速度18r/min，混合5分钟；
步骤4：将步骤3中得到的物料然后置于旋转压片机上，压制成单片500mg、硬度80N～160N的椭圆形片芯；
步骤5：将步骤4中得到的素片用胃溶型薄膜包衣预混剂(欧巴代)进行包衣，得到薄膜包衣片。
实施例3-4
依达拉奉缓释片处方组成
Figure PCTCN2021114757-appb-000003
Figure PCTCN2021114757-appb-000004
制备工艺：
步骤1：将上述处方中的依达拉奉和HPMCAS加入到溶剂中(甲醇：水＝9:1)，将样品置于恒温水浴锅中搅拌，设置加热温度50℃，进行溶解；
步骤2：将步骤1中的溶液使用喷雾干燥机进行喷雾干燥，得依达拉奉固体分散体，将依达拉奉固体分散体过40目筛网；
步骤3：将步骤2中处理好的依达拉奉固体分散体与除硬脂酸镁外的其他辅料置于三维混合机中，设置混合速度18r/min，混合20分钟；再加入内加的硬脂酸镁，设置混合速度18r/min，混合5分钟；
步骤4：将步骤3得到的混合物置于干法制粒机中，调节设备参数，使之能压制成有一定硬度的大片，再用1.0mm筛网进行整粒；再与外加的硬脂酸镁混合，设置混合速度18r/min，混合5分钟；
步骤5：将步骤4中得到的物料然后置于旋转压片机上，压制成单片600mg、硬度100N～180N的椭圆形片芯；
步骤6：将步骤5中得到的素片用胃溶型薄膜包衣预混剂(欧巴代)进行包衣，得到薄膜包衣片。
实施例5
对以上所制得的依达拉奉缓释片进行释放度测定，所述释放度的测定方法如下：取缓释片剂(n＝12)，照中国药典2020版二部附录XC第二法，以pH6.8磷酸盐缓冲溶液900ml为溶出介质，转速为50r/min，于1，2，4，6，8，12，16，20，24小时取溶液1.5ml，经10μm的微孔滤膜滤过，采用高效液相(HPLC)方法检测药物累积释放度。溶出结果如下：
Figure PCTCN2021114757-appb-000005
实施例6
依达拉奉在各pH水溶液中的溶解度均较低，小于1mg/ml，生物利用度低，因此本实施例中使用了聚合物载体，将依达拉奉制备成固体分散体后，溶解度结果如下：
样品 溶解度(mg/ml)
依达拉奉 0.40
依达拉奉：HPMCAS＝1:1 2.48
依达拉奉：HPMCAS＝1:3 6..28
依达拉奉：HPMCAS＝1:5 10.25
结果表明，依达拉奉与醋酸羟丙甲纤维素琥珀酸酯制备成固体分散体后，其溶解度提高了6～25倍，因此本发明中将依达拉奉制备成无定形的固体分散体，有利于提高其溶解度，可提高生物利用度；制备成缓释剂型，可使体内血药浓度平稳，降低毒副作用。

Claims (10)

  1. 一种药物组合物，其中所述药物组合物具有以下特征A)、B)和C)：
    A)在1小时内溶出不超过35％的药物活性成分；
    B)在6小时内溶出30％～65％的药物活性成分；
    C)在24小时内溶出不低于75％的药物活性成分；
    其中，所述的药物活性成分可以选自依达拉奉、其药学上可接受的盐、水合物和溶剂合物中的一种或多种；
    优选地，所述药物组合物优选具有以下特征A)、B)和C)：
    A)在1小时内溶出不超过30％的药物活性成分；
    B)在6小时内溶出30％～60％的药物活性成分；
    C)在24小时内溶出不低于75％的药物活性成分；
    更优选地，所述药物组合物更优选具有以下特征A)、B)和C)：
    A)在1小时内溶出不超过25％的药物活性成分；
    B)在6小时内溶出35％～60％的药物活性成分；
    C)在24小时内溶出不低于80％的药物活性成分。
  2. 一种药物组合物，其特征在于包括以下组分：药物层和包衣层；所述的药物层包括依达拉奉药物活性成分、聚合物载体、骨架缓释材料和其他辅料；所述的其他辅料包括填充剂、粘合剂、崩解剂和润滑剂中的一种或多种；
    所述的依达拉奉药物活性成分包括依达拉奉、依达拉奉药学上可接受的盐、依达拉奉水合物和依达拉奉溶剂合物中的一种或多种；
    优选地，所述的依达拉奉药物活性成分的含量为5.0％～65.0％，所述的含量是指以依达拉奉计，依达拉奉药物活性成分的重量占药物组合物总重量的百分比；
    优选地，所述的包衣层为薄膜包衣；
  3. 如权利要求2所述的药物组合物，其特征在于：
    所述的聚合物载体选自聚乙二醇、共聚维酮、羟丙甲纤维素、醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯、聚醋酸乙烯酯聚维酮混合物、泊洛沙姆和羧甲基乙基纤维素中的一种或多种；
    优选地，所述的聚合物载体的含量为10.0％～80.0％，所述的含量是指聚合物载体的重量占药物组合物总重量的百分比；
    所述的骨架缓释材料选自羟丙基甲基纤维素、羟丙基纤维素、海藻酸钠、羧甲基纤维素、羧甲基纤维素钠、甲基纤维素、聚丙烯酸树脂、乙基纤维素、卡波姆、硬脂酸、聚氧乙烯、聚醋酸乙烯酯聚维酮混合物、单硬脂酸甘油酯、双硬脂酸甘油酯、山嵛酸甘油酯、十六醇、十八醇、蜂蜡、氢化蓖麻油、巴西棕榈蜡、石蜡、白蜡和微晶蜡中的一种或多种；
    优选地，所述的骨架缓释材料的含量为5.0％～50.0％，所述的含量是指骨架缓释材料的重量占药物组合物总重量的百分比。
  4. 如权利要求2所述的药物组合物，其特征在于：
    所述的填充剂选自微晶纤维素、预胶化淀粉、淀粉、乳糖、甘露醇、磷酸氢钙和硅化微晶纤维素中的一种或多种；
    所述的粘合剂选自聚维酮、甲基纤维素、羟丙基甲基纤维素、羟乙基纤维素、共聚维酮、羧甲基纤维素钠、羟丙基纤维素和海藻酸钠中的一种或多种；
    所述的润滑剂选自硬脂酸钙、硬脂酸镁、硬脂酸锌、硬脂酸、硬脂酸富马酸钠、聚乙二醇、淀粉、滑石粉和石蜡中的一种或多种；
    所述的崩解剂选自交联聚维酮、交联羧甲基纤维素钠、交联羧甲基纤维素钙、羧甲基淀粉钠，羟丙纤维素和预胶化淀粉中的一种或多种；
    所述的填充剂的含量优选10.0％～60.0％，其中，所述的含量是指填充剂的重量占药物组合物总重量的百分比；
    所述的粘合剂的含量优选5.0％～30.0％，其中，所述的含量是指粘合剂 的重量占药物组合物总重量的百分比；
    所述的润滑剂的含量优选0％～5％，其中，所述的含量是指润滑剂的重量占药物组合物总重量的百分比；
    所述的其他辅料的含量为30.0％～80.0％，所述的含量是指其他辅料的重量占药物组合物总重量的百分比。
  5. 如权利要求2所述的药物组合物，其特征在于：所述的药物组合物选自具有以下重量百分比的任一组分：
    组分一：10.0％-30.0％依达拉奉药物活性成分，10.0％-30.0％醋酸羟丙甲纤维素琥珀酸酯，10.0％-30.0％羟丙甲纤维素K4M，5.0％-20.0％羟丙甲纤维素K100Lv，10.0％-30.0％乳糖，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
    组份二：10.0％-30.0％依达拉奉药物活性成分，10.0％-30.0％醋酸羟丙甲纤维素琥珀酸酯，10.0％-30.0％羟丙甲纤维素K100Lv，10.0％-30.0％预胶化淀粉，5.0％-20.0％交联聚维酮，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
    组分三：10.0％-30.0％依达拉奉药物活性成分、40.0％-60.0％醋酸羟丙甲纤维素琥珀酸酯，5.0％-20.0％羟丙甲纤维素K4M，5.0％-20.0％羟丙甲纤维素K100Lv，5.0％-20.0％乳糖，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
    组分四：10.0％-30.0％依达拉奉药物活性成分，40.0％-60.0％醋酸羟丙甲纤维素琥珀酸酯，5.0％-20.0％羟丙甲纤维素K100Lv，5.0％-20.0％预胶化淀粉，5.0％-20.0％交联聚维酮，5.0％-20.0％微晶纤维素和0.5％-2.0％硬脂酸镁；
    优选地，所述的药物组合物选自具有以下重量的任一组分：
    组分一：20.00％依达拉奉药物活性成分，20.00％醋酸羟丙甲纤维素琥珀酸酯，20.00％羟丙甲纤维素K4M，10.00％羟丙甲纤维素K100Lv，19.00％乳糖，10.00％微晶纤维素和1.00％硬脂酸镁；
    组份二：20.00％依达拉奉药物活性成分，20.00％醋酸羟丙甲纤维素琥珀 酸酯，19.00％羟丙甲纤维素K100Lv，20.00％预胶化淀粉，10.00％交联聚维酮，10.00％微晶纤维素和1.00％硬脂酸镁；
    组分三：16.67％依达拉奉药物活性成分、50.00％醋酸羟丙甲纤维素琥珀酸酯，8.33％羟丙甲纤维素K4M，8.33％羟丙甲纤维素K100Lv，8.33％乳糖，7.34％微晶纤维素和1.00％硬脂酸镁；
    组分四：16.67％依达拉奉药物活性成分，50.00％醋酸羟丙甲纤维素琥珀酸酯，8.33％羟丙甲纤维素K100Lv，8.33％预胶化淀粉，7.34％交联聚维酮，8.33％微晶纤维素和1.00％硬脂酸镁。
  6. 如权利要求2所述的药物组合物，其特征在于：所述的药物组合物为缓释片、缓释胶囊和缓释微丸。
  7. 如权利要求1-6任一项所述的药物组合物的制备方法，其特征在于：所述制备方法选自湿法制粒法、干法制粒法和直接压片法。
  8. 如权利要求7所述的药物组合物的制备方法，其特征在于：
    所述的湿法制粒包括以下步骤：将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中，经喷雾干燥得依达拉奉药物活性成分固体分散体；
    将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料混合，湿法制粒，干燥，整粒，然后再与润滑剂混合，压片，包衣，即得到依达拉奉药物活性成分缓释片，所述的部分其他辅料包括粘合剂、填充剂和崩解剂中的一种或多种；
    所述的干法制粒包括以下步骤：将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中，经喷雾干燥得依达拉奉药物活性成分固体分散体；
    将依达拉奉药物活性成分固体分散体与骨架缓释材料及部分其他辅料，干法制粒，然后再与外加润滑剂混合，压片，包衣即得到依达拉奉药物 活性成分缓释片，所述的部分其他辅料包括粘合剂、填充剂、崩解剂和润滑剂中的一种或多种；
    所述的直接压片法包括以下步骤：将依达拉奉药物活性成分和醋酸羟丙甲纤维素琥珀酸酯溶解于甲醇/水溶液中，经喷雾干燥得依达拉奉药物活性成分固体分散体；
    将依达拉奉药物活性成分固体分散体与骨架缓释材料和其他辅料混合，压片，包衣得到依达拉奉药物活性成分缓释片。
  9. 如权利要求1-6任一项所述的药物组合物在制备和/或预防氧化性应激相关疾病的药物中的应用；
    优选地，所述的氧化性应激相关疾病选自老年痴呆症、肌萎缩侧索硬化症、帕金森氏病、缺血性心脏病、脑梗/中风、血栓性静脉炎、慢性阻塞性肺疾病、人类免疫系统病/获得性免疫系统综合症和糖尿病。
  10. 一种治疗和/或预防氧化性应激相关疾病的方法，包括将所述药物组合物给予有需要的患者(例如人)；
    优选地，所述的氧化性应激相关疾病选自老年痴呆症、肌萎缩侧索硬化症、帕金森氏病、缺血性心脏病、脑梗/中风、血栓性静脉炎、慢性阻塞性肺疾病、人类免疫系统病/获得性免疫系统综合症和糖尿病。
PCT/CN2021/114757 2020-08-26 2021-08-26 依达拉奉缓释药物组合物、制备方法及应用 WO2022042644A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010871330.3 2020-08-26
CN202010871330 2020-08-26

Publications (1)

Publication Number Publication Date
WO2022042644A1 true WO2022042644A1 (zh) 2022-03-03

Family

ID=80352731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/114757 WO2022042644A1 (zh) 2020-08-26 2021-08-26 依达拉奉缓释药物组合物、制备方法及应用

Country Status (2)

Country Link
CN (1) CN114099500B (zh)
WO (1) WO2022042644A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN109125261A (zh) * 2016-03-16 2019-01-04 苏州澳宗生物科技有限公司 依达拉奉剂型
CN109431966A (zh) * 2018-04-27 2019-03-08 首都医科大学附属北京天坛医院 依达拉奉药物组合物
CN109906077A (zh) * 2016-08-29 2019-06-18 烟台益诺依生物医药科技有限公司 依达拉奉与(+)-2-莰醇的舌下用药物组合物
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
CN110384656A (zh) * 2018-04-19 2019-10-29 上海现代药物制剂工程研究中心有限公司 依达拉奉鼻腔给药组合物及其鼻给药制剂制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
CN104814923B (zh) * 2014-08-21 2017-09-12 浙江海力生制药有限公司 一种盐酸坦洛新缓释制剂及其制备方法和其应用
CN104490838B (zh) * 2014-11-20 2017-03-01 河北医科大学 一种骨架型缓控释片剂及其制备方法和应用
CN105534940B (zh) * 2016-02-19 2018-12-07 国药集团致君（深圳）坪山制药有限公司 一种双氯芬酸钠缓释片组合物及其制备方法
RU2693627C2 (ru) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинации эдаравона для лечения ишемических повреждений мозга

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN109125261A (zh) * 2016-03-16 2019-01-04 苏州澳宗生物科技有限公司 依达拉奉剂型
CN109906077A (zh) * 2016-08-29 2019-06-18 烟台益诺依生物医药科技有限公司 依达拉奉与(+)-2-莰醇的舌下用药物组合物
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
CN110461325A (zh) * 2017-01-17 2019-11-15 萃微Tw001公司 包括口服或胃部施用依达拉奉的治疗
CN110384656A (zh) * 2018-04-19 2019-10-29 上海现代药物制剂工程研究中心有限公司 依达拉奉鼻腔给药组合物及其鼻给药制剂制备方法
CN109431966A (zh) * 2018-04-27 2019-03-08 首都医科大学附属北京天坛医院 依达拉奉药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIć SINIšA; MAIER NORBERT M.; RIZZI ANDREAS M.: "Quantitative profiling ofO-glycans by electrospray ionization- and matrix-assisted laser desorption ionization-time-of-flight-mass spectrometry afterin-gelderivatization with isotope-coded 1-phenyl-3-methyl-5-pyrazolone", ANALYTICA CHIMICA ACTA, vol. 935, 22 June 2016 (2016-06-22), AMSTERDAM, NL , pages 187 - 196, XP029687903, ISSN: 0003-2670, DOI: 10.1016/j.aca.2016.06.032 *

Also Published As

Publication number Publication date
CN114099500A (zh) 2022-03-01
CN114099500B (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
TWI241911B (en) Sustained release ranolazine formulations
JP5816091B2 (ja) ナトリウムオキシベートの即時放出投薬形態
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
KR20070115918A (ko) 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
WO2022012172A1 (zh) 一种难溶性药物口服缓释组合物及其制备方法
WO2021238978A1 (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
KR100798730B1 (ko) 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
KR20190064215A (ko) 토파시티닙을 포함하는 약제학적 조성물
US11382912B2 (en) Controlled-release preparation
EP2603207A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2019237446A1 (zh) 一种曲美他嗪缓释片及其制备方法
WO2022042645A1 (zh) 依达拉奉口服持续释放组合物、制备方法及应用
US20100272794A1 (en) Pharmaceutical composition of memantine
WO2022042644A1 (zh) 依达拉奉缓释药物组合物、制备方法及应用
TW202227071A (zh) 為單片基質錠劑形式之控釋型含瑞巴派特醫藥組成物及其製備程序
CN115297848A (zh) 一种非布司他片
US20080081069A1 (en) Novel controlled release formulations of divalproex sodium
WO2024140984A1 (zh) 一种洛索洛芬钠的控释片、制备方法及应用
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
KR20060130006A (ko) 경구 서방성 정제
TWI823471B (zh) 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
JP2016098230A (ja) 末梢血管疾患を有する患者における間欠跛行の症状を軽減するために用いられるキノリノン誘導体シロスタゾールの新規製剤
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21860478

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21860478

Country of ref document: EP

Kind code of ref document: A1